http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020113856-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13d11c9410907b316838cf0294cb9b95 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-9068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-534 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-9068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-534 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
filingDate | 2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e4e95a8a77baa3bc658090d14ef99f |
publicationDate | 2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2020113856-A1 |
titleOfInvention | Non-prescription motion sickness medication containing an analgesic, an h2 blocker, and at least one antacid |
abstract | The present invention provides a compounded non-prescription medication for the treatment of motion sickness. The medication comprises: at least one analgesic selected from the group consisting of acetaminophen, ibuprofen, naproxen and salicylates; at least one histamine H 2 -receptor antagonist selected from the group consisting of nizatidine, famotidine, cimetidine, ranitidine. famotidine; and at least one antacid selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and bismuth subsalicylate. The medication may optionally comprise at least one additional ingredient selected from the group consisting of spearmint extract and ginger extract. The formulations are consistent in their effectiveness and devoid of the side effects of drowsiness and dry mouth. A presently preferred embodiment of the medication comprises primarily of ibuprofen, famotidine, calcium carbonate, magnesium hydroxide, spearmint extract and ginger extract. |
priorityDate | 2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.